Hodgkin's Lymphoma

Hodgkin's lymphoma, previously known as Hodgkin's disease, is a type of lymphoma, which is a type of cancer originating from white blood cells called lymphocytes. It was named after Thomas Hodgkin, who first described abnormalities in the lymph system in 1832.
What is Hodgkin's Lymphoma?

Hodgkin’s lymphoma or Hodgkin’s disease is a form of cancer that affects the lymphatic system. The cancer originates in the lymphocytes, which are white blood cells. The disease was so named after Thomas Hodgkin, who first described the condition in 1832.

Read More

Overview

Feature Articles

Latest Hodgkin's Lymphoma News and Research

Heart transplant recipient's journey: From patient to advocate

Heart transplant recipient's journey: From patient to advocate

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

High BMI in late teens linked to higher risk of 17 different cancers later in life

High BMI in late teens linked to higher risk of 17 different cancers later in life

Associations between alcohol intake, cancer risk, and modifying factors in women: smoking, BMI, and MHT interactions

Associations between alcohol intake, cancer risk, and modifying factors in women: smoking, BMI, and MHT interactions

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

Analyzing the role of LP-284 Hodgkin's lymphoma models and in DNA damage repair

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

2023 PCRF grant recipients announced for exploring new, safer treatments for pediatric cancers

Formerly incarcerated persons have higher health risks than the general population

Formerly incarcerated persons have higher health risks than the general population

Chemotherapy in the afternoon proved to be effective for female lymphoma patients

Chemotherapy in the afternoon proved to be effective for female lymphoma patients

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

Inhibiting inflammatory signaling pathway could reduce the chances of heart disease in cancer survivors

Inhibiting inflammatory signaling pathway could reduce the chances of heart disease in cancer survivors

Addition of brentuximab vedotin to chemotherapy has a positive impact for patients with Hodgkin lymphoma

Addition of brentuximab vedotin to chemotherapy has a positive impact for patients with Hodgkin lymphoma

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Zentalis contributes $1 million to SU2C Catalyst program for research into targeted cancer therapeutics

Damon Runyon Cancer Research Foundation announces newest cohort of Fellows and Breakthrough Scientists

Damon Runyon Cancer Research Foundation announces newest cohort of Fellows and Breakthrough Scientists

International collaboration secures €1M grant to investigate new treatment target for lymphoma

International collaboration secures €1M grant to investigate new treatment target for lymphoma

First detection of SARS-CoV-2 remdesivir resistance in an immunocompromised patient

First detection of SARS-CoV-2 remdesivir resistance in an immunocompromised patient

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients

Biomarker shows potential to predict immunotherapy benefit for breast cancer patients

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

Wistar researchers discover new enzymatic function of the Epstein-Barr Virus protein

Wistar researchers discover new enzymatic function of the Epstein-Barr Virus protein

MDC researchers develop a potent weapon against lymphomas

MDC researchers develop a potent weapon against lymphomas

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.